KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) EPS (Basic) (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed EPS (Basic) for 16 consecutive years, with -$1.16 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) fell 207.41% to -$1.16 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.65 through Dec 2025, down 24.29% year-over-year, with the annual reading at $2.64 for FY2025, 24.57% down from the prior year.
  • EPS (Basic) for Q4 2025 was -$1.16 at Halozyme Therapeutics, down from $1.49 in the prior quarter.
  • The five-year high for EPS (Basic) was $1.53 in Q3 2021, with the low at -$1.16 in Q4 2025.
  • Average EPS (Basic) over 5 years is $0.63, with a median of $0.62 recorded in 2023.
  • The sharpest move saw EPS (Basic) soared 600.0% in 2021, then crashed 207.41% in 2025.
  • Over 5 years, EPS (Basic) stood at $0.47 in 2021, then decreased by 8.51% to $0.43 in 2022, then soared by 51.16% to $0.65 in 2023, then soared by 66.15% to $1.08 in 2024, then plummeted by 207.41% to -$1.16 in 2025.
  • According to Business Quant data, EPS (Basic) over the past three periods came in at -$1.16, $1.49, and $1.36 for Q4 2025, Q3 2025, and Q2 2025 respectively.